This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/6/950    most recent ATVBAHA.108.178228v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Taskinen, M.-R. PubMed PubMed Citation Articles by Taskinen, M.-R.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:950.)
© 2009 American Heart Association, Inc.

Clinical and Population Studies

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

Marja-Riitta Taskinen; David R. Sullivan; Christian Ehnholm; Malcolm Whiting; Diana Zannino; R. John Simes; Anthony C. Keech; Philip J. Barter for the FIELD study investigators

From the Department of Medicine (M.-R.T.), Helsinki University Central Hospital, Biomedicum, Helsinki, Finland; the Department of Clinical Biochemistry (D.R.S.), Royal Prince Alfred Hospital, Camperdown, NSW Australia; the Department of Molecular Medicine (C.E.), National Public Health Institute, Biomedicum, Helsinki, Finland; the Department of Medical Chemistry (M.W.), Flinders Medical Centre, South Australia, Australia; NHMRC Clinical Trials Centre (D.Z., R.J.S., A.C.K.), University of Sydney, Australia; The Heart Research Institute (P.J.B.), University of Sydney, Australia.

Correspondence to Dr Marja-Riitta Taskinen, Department of Medicine, Division of Cardiology, Helsinki University Hospital, Biomedicum, Haartmaninkatu 8, 00029 Helsinki, Finland. E-mail Marja-Riitta.Taskinen{at}helsinki.fi

Objective— The purpose of this study was to determine fenofibrate-induced changes in plasma high-density lipoprotein cholesterol (HDL-C), apoliprotein (apo) A-I, and apolipoprotein (apo) A-II and how they relate to changes in plasma homocysteine and creatinine.

Methods and Results— FIELD was a double-blind placebo-controlled trial done in Australia, New Zealand, and Finland. All FIELD subjects were included except those who started statin therapy or permanently discontinued fenofibrate. Patients were randomized to receive daily micronised fenofibrate (200 mg) or matching placebo and were followed up for a median of 5 years. Plasma HDL-C, apoA-I, apoA-II, homocysteine, and creatinine were measured. There was an inverse relationship between baseline homocysteine levels and HDL-C in the placebo (P=0.07 for linear trend) and fenofibrate groups (P<0.0001) and apoA-I (P<0.001, both groups). The increases in homocysteine and creatinine in the fenofibrate group correlated positively (P<0.0001). The greater the increase in homocysteine induced by fenofibrate, the smaller the increases in HDL-c and apoA-I (P<0.0001 for linear trends). There was a highly significant and positive relationship between fenofibrate-induced changes in homocysteine and apoA-II levels.

Conclusions— PPAR agonists that have a more robust effect on HDL-C and apoA-I would be desirable.

Key Words: type 2 diabetes • lipid and lipoprotein metabolism • fibrates • homocysteine • HDL